Kevin Fitzgerald

Patient-centric executive with 23 year career marked by developing drugs that impact disease progression and outcomes, while leveraging novel technologies. Data-driven leader skilled in building relationships with staff, team members, alliance partners, and key opinion leaders. Proven success in drug development and delivery spanning small molecule, oligonucleotide, nanoparticles, liposomes, and conjugates. Co-inventor of 4 FDA approved RNAi therapeutics with many others in clinical development. Accomplished public speaker, published author in NEJM, Nature,Cell, and others. Expertise in orphan disease drug development, oncology, metabolic diseases, human genetics, and complex drug delivery systems. SAB and BOD experience.